Ductal Breast Carcinoma in Situ Clinical Trial
— NORDISOfficial title:
A Randomized Phase II Study Comparing Surgical Excision Versus Neoadjuvant Radiotherapy Followed by Delayed Surgical Excision of Ductal Carcinoma In Situ (NORDIS)
The purpose of this pilot study is to compare by pathological findings surgical excision versus neoadjuvant radiotherapy followed by delayed surgical excision of ductal carcinoma in situ (DCIS)
Status | Recruiting |
Enrollment | 50 |
Est. completion date | July 2025 |
Est. primary completion date | September 2024 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria - Core needle biopsy demonstrating DCIS (ductal carcinoma in situ) of non-palpable, image-detected breast abnormality - Signed and dated IRB-approved written informed consent - Women 18 years of age or older - Mammographic calcifications or MRI non-mass enhancement measuring 4 cm or less in greatest dimension, including multifocal disease - Estrogen receptor positive or negative, progesterone receptor positive or negative DCIS; HER2 positive, negative or unknown DCIS is allowed. - Diagnostic needle biopsy within 16 weeks of randomization - Patients must have a biopsy marker placed within the tumor bed confirmed on post biopsy imaging and evidence of residual radiographic abnormality. Confirmation of residual imaging abnormality is required within 6 weeks of randomization. - Placement of Savi scout optical reflectance marker in tumor bed area as a wireless guide for surgery and for neoRT treatment planning is preferred but not required if anatomic metallic markers are sufficient for radiation planning. Placement does not have to occur before randomization. Additionally, wire localization before surgery is permissible. - Planned lumpectomy. Mastectomy will be acceptable if lumpectomy fails by virtue of involved margins or size of lesion, or patient chooses this approach after randomization - Radiation Oncologist to ascertain feasibility of PBI prior to randomization - based on their estimation that 30% or less of the breast volume will be encompassed in the radiation fields - Patients who had a prior contralateral invasive or non-invasive (DCIS) cancer are eligible - ECOG performance status 0, 1, or 2 - Concurrent foci of atypia or lobular carcinoma in situ in the ipsilateral or contralateral breast are allowed Exclusion Criteria - Invasive carcinoma on core needle biopsy, including microinvasive carcinoma - Radiographic extent of DCIS >4.0 cm - Mass lesion on breast imaging or palpable tumor - No residual radiographic lesion after diagnostic percutaneous core needle biopsy - Prior history of ipsilateral invasive or noninvasive breast cancer - Pregnant or breastfeeding - Prior ipsilateral breast or chest irradiation - Multicentric or multifocal DCIS, if extent is > 4cm - Synchronous contralateral invasive or noninvasive breast cancer - Pagets' disease of the breast - Active collagen vascular disease - Positive axillary lymph nodes - Not meeting the described criteria for partial breast irradiation during initial clinical evaluation. - Psychiatric or addictive disorders or other condition, that, in the opinion of the investigator, would preclude the patient from meeting the study requirements or interfere with the interpretation of study results - Endocrine therapy is not allowed from the time of study randomization to the completion of surgery unless the endocrine therapy is being continued for a contralateral cancer |
Country | Name | City | State |
---|---|---|---|
United States | Stanford University | Stanford | California |
Lead Sponsor | Collaborator |
---|---|
Stanford University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of ductal carcinoma in situ (DCIS) pathologic complete response | A DCIS pathologic complete response will be defined as the absence of in situ carcinoma in the surgical resection specimen. The rate of DCIS pathologic complete response (pCR) will be calculated for Arm 1 and Arm 2. | 12 weeks | |
Secondary | Correlation of ductal carcinoma in situ (DCIS) subtypes with rate of DCIS pathologic complete response to neoadjuvant partial breast irradiation (PBI) | Molecular subtypes based on gene expression profiling with therapy response will be corelated.
• DCIS subtypes will be defined based on grade, estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status as follows: Low/intermediate grade versus high grade ER/PR-negative versus ER/PR-positive HER2-positive versus HER2-negative |
12 weeks | |
Secondary | Tumor grade comparison of radiation-induced treatment effect pathologically pre- versus post-therapy | Tumor grade (grade 1, 2, 3) will be compared pre- and post-therapy. | 12 weeks | |
Secondary | Nuclear atypia comparison of radiation-induced treatment effect pathologically pre- versus post-therapy | Degree of nuclear atypia (low, intermediate, high) will be compared pre- and post-therapy. | 12 weeks | |
Secondary | Percent tumor necrosis comparison of radiation-induced treatment effect pathologically pre- versus post-therapy | Percent tumor necrosis (0-100%) will be quantified on the basis of percentage of overall residual tumor area and compared pre- and post-treatment. | 12 weeks | |
Secondary | Tumor cellularity comparison of radiation-induced treatment effect pathologically pre- versus post-therapy | Tumor cellularity (0-100%) will be quantified on the basis of percentage of overall residual tumor area and compared pre- and post-treatment. | 12 weeks | |
Secondary | Proportion of subjects experiencing a wound complication on Arm 1 compared to Arm 2 | Wound complications and healing will be monitored in both arms.The following events will be considered wound complications: wound dehiscence, hematoma requiring intervention, seroma requiring drainage, skin necrosis requiring resection, cellulitis requiring antibiotic therapy. | 12 weeks | |
Secondary | Correlation of post-radiation imaging characteristics with pathologic findings | Mammography obtained prior to surgical resection in Arm 2 patients will be assessed for the presence or absence of a residual mammographic abnormality, the size in mm of the residual mammographic abnormality and the longest span in mm of residual calcification and will be compared to the pathologic presence or absence of residual tumor, size in mm of the pathologic residual DCIS and whether the residual calcification is associated with pathologic residual DCIS. | 12 weeks | |
Secondary | Rate of invasive carcinoma comparison in Arm 1 to Arm 2 | Rate of pathologic residual invasive carcinoma will be assessed in Arm 1 and Arm 2. | 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02314156 -
Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy
|
Phase 2 | |
Completed |
NCT01874184 -
Group-Based Lifestyle Intervention in Measuring Biomarker Levels in Participants at High Risk for Breast Cancer
|
N/A | |
Active, not recruiting |
NCT01905046 -
Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer
|
Phase 3 | |
Completed |
NCT01869764 -
Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer
|
Phase 2 | |
Completed |
NCT02587663 -
Extent of Breast Cancer and the Role of Pre-Operative Sonography and MRI
|
N/A | |
Active, not recruiting |
NCT04537312 -
Prospective Pilot Study of Robot-assisted Nipple Sparing Mastectomy (RNSM)
|
N/A | |
Active, not recruiting |
NCT01245712 -
Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer
|
Phase 2 | |
Recruiting |
NCT02993159 -
Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast
|
Phase 2 | |
Completed |
NCT01753908 -
Broccoli Sprout Extract in Treating Patients With Breast Cancer
|
Early Phase 1 | |
Terminated |
NCT02023008 -
Interactive Gentle Yoga in Improving Quality of Life in Patients With Stage I-III Breast Cancer Undergoing Radiation Therapy
|
N/A | |
Terminated |
NCT01754519 -
Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery
|
Phase 2 | |
Completed |
NCT01849250 -
Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors
|
Phase 2 | |
Completed |
NCT01819233 -
Caloric Restriction in Treating Patients With Stage 0-I Breast Cancer Undergoing Surgery and Radiation Therapy
|
N/A | |
Active, not recruiting |
NCT03077841 -
Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT02352883 -
MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ
|
N/A | |
Completed |
NCT01723943 -
Educational Counseling in Improving Communication and Quality of Life in Spouses and Breast Cancer Patients
|
N/A | |
Completed |
NCT00637481 -
A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer
|
Phase 1 | |
Completed |
NCT01975363 -
Pilot Study of Curcumin for Women With Obesity and High Risk for Breast Cancer
|
N/A | |
Active, not recruiting |
NCT03391388 -
3D-CRT, Proton, or Brachytherapy APBI in Treating Patients With Invasive and Non-invasive Breast Cancer
|
Phase 2 | |
Completed |
NCT02526498 -
Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery
|
Phase 2 |